Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed HER2-positive metastatic breast cancer~* On treatment with first-line trastuzumab IV and free of disease progression for at least 3 years~* Left ventricular ejection fraction (LVEF) of greater than or equal to (\>/=) 50 percent (%)~* Hormonal therapy will be allowed~* Prior use of anti-HER2 therapy will be allowed~Exclusion Criteria:~* History of other malignancy, except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma and participants with other curatively treated malignancies who have been disease-free for at least 5 years; participants with previous ductal carcinoma in situ of the breast are also eligible~* Participants with severe dyspnea at rest or requiring supplementary oxygen therapy~* Serious cardiac illness or medical conditions that would preclude the use of trastuzumab~* Hepatitis B, hepatitis C or human immunodeficiency virus infection~* Pregnant or lactating women~* Concurrent enrollment in an other clinical trial using an investigational anti-cancer treatment, including hormonal therapy, biphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment~* Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of Herceptin including hyaluronidase or the adhesive of the subcutaneous device, or a history of severe allergic or immunological reactions, for example, difficult to control asthma~* Central nervous system metastases, unless they have been treated and have been stable for at least 3 years~* Inadequate organ function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab IV Then Trastuzumab SC (Type: EXPERIMENTAL): Participants will receive treatment with Trastuzumab IV for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab SC for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
- Trastuzumab SC Then Trastuzumab IV (Type: EXPERIMENTAL): Participants will receive treatment with Trastuzumab SC for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab IV for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).